MRPS33

Across TCGA pan-cancer cohorts, MRPS33 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated MRPS33 data layer compared with 22 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher MRPS33 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated MRPS33 expression acts as an unfavorable survival marker, although some lineages such as LSCC and PDAC show a favorable association.

LSCC, PDAC, and GBM are the cancer types where MRPS33 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	OS	Tertile	II,III,IV	1.000	0.600	.001	15	view →
PDAC	OS	Tertile	All	0.542	0.303	.036	4	view →
GBM	OS	Tertile	All	0.663	0.465	.030	3	view →
LUAD	DFS	Median	III,IV	0.409	0.941	.010	3	view →
CCRCC	DFS	Tertile	All	1.000	0.570	.027	2	view →
HNSC	DFS	Tertile	III,IV	0.904	1.000	.032	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

MRPS33–LSCC (OS)

Open the LSCC breakdown →